Gilead Sciences (GILD) EPS (Basic) (2009 - 2026)

Gilead Sciences (GILD) has reported EPS (Basic) for 18 consecutive years, with -$8.44 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) fell 636.1% year-over-year to -$8.44; the trailing twelve-month figure through Jun 2026 stood at -$2.33 (down 145.95% YoY), and the FY2025 full-year result was $6.84, up 1680.9% from the prior year.
• EPS (Basic) retreated to -$8.44 in Q2 2026 per GILD's latest filing, from $1.63 in the prior quarter.
• Across five years, EPS (Basic) topped out at $2.46 in Q3 2025 and bottomed at -$8.44 in Q2 2026.
• Historically, EPS (Basic) has averaged $0.49 across 5 years, with a median of $1.21 in 2023.
• The sharpest annual moves came in 2023 and 2026: EPS (Basic) surged 8145.99% in 2023, then sank 636.1% in 2026.
• Over 5 years, EPS (Basic) stood at $1.3 in 2022, then decreased by 12.8% to $1.13 in 2023, then increased by 25.95% to $1.43 in 2024, then soared by 42.21% to $2.03 in 2025, then plunged by 515.52% to -$8.44 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$8.44, $1.63, and $2.03 for Q2 2026, Q1 2026, and Q4 2025 respectively.